Titre : Syndrome de Denys-Drash

Syndrome de Denys-Drash : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndrome de Denys-Drash : Questions médicales les plus fréquentes", "headline": "Syndrome de Denys-Drash : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndrome de Denys-Drash : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-15", "dateModified": "2025-04-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndrome de Denys-Drash" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles du développement sexuel de sujets 46, XY", "url": "https://questionsmedicales.fr/mesh/D058490", "about": { "@type": "MedicalCondition", "name": "Troubles du développement sexuel de sujets 46, XY", "code": { "@type": "MedicalCode", "code": "D058490", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C19.391.119.096" } } }, "about": { "@type": "MedicalCondition", "name": "Syndrome de Denys-Drash", "alternateName": "Denys-Drash Syndrome", "code": { "@type": "MedicalCode", "code": "D030321", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Kentaro Nishi", "url": "https://questionsmedicales.fr/author/Kentaro%20Nishi", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development." } }, { "@type": "Person", "name": "Koichi Kamei", "url": "https://questionsmedicales.fr/author/Koichi%20Kamei", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development." } }, { "@type": "Person", "name": "Masao Ogura", "url": "https://questionsmedicales.fr/author/Masao%20Ogura", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development." } }, { "@type": "Person", "name": "Mai Sato", "url": "https://questionsmedicales.fr/author/Mai%20Sato", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development." } }, { "@type": "Person", "name": "Kandai Nozu", "url": "https://questionsmedicales.fr/author/Kandai%20Nozu", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Kobe University Graduate School of Medicine." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36253300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clgc.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.", "datePublished": "2024-10-20", "url": "https://questionsmedicales.fr/article/39428439", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-76355-4" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies endocriniennes", "item": "https://questionsmedicales.fr/mesh/D004700" }, { "@type": "ListItem", "position": 3, "name": "Troubles gonadiques", "item": "https://questionsmedicales.fr/mesh/D006058" }, { "@type": "ListItem", "position": 4, "name": "Troubles du développement sexuel", "item": "https://questionsmedicales.fr/mesh/D012734" }, { "@type": "ListItem", "position": 5, "name": "Troubles du développement sexuel de sujets 46, XY", "item": "https://questionsmedicales.fr/mesh/D058490" }, { "@type": "ListItem", "position": 6, "name": "Syndrome de Denys-Drash", "item": "https://questionsmedicales.fr/mesh/D030321" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndrome de Denys-Drash - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndrome de Denys-Drash", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndrome de Denys-Drash", "description": "Comment diagnostique-t-on le syndrome de Denys-Drash ?\nQuels tests génétiques sont utilisés ?\nQuels signes cliniques indiquent ce syndrome ?\nLes échographies sont-elles utiles ?\nLe syndrome est-il héréditaire ?", "url": "https://questionsmedicales.fr/mesh/D030321?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndrome de Denys-Drash", "description": "Quels sont les symptômes principaux ?\nY a-t-il des signes de dysfonctionnement hormonal ?\nLes enfants sont-ils affectés dès la naissance ?\nLe syndrome affecte-t-il la croissance ?\nY a-t-il des symptômes psychologiques associés ?", "url": "https://questionsmedicales.fr/mesh/D030321?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndrome de Denys-Drash", "description": "Peut-on prévenir le syndrome de Denys-Drash ?\nComment le conseil génétique aide-t-il ?\nLes tests prénataux sont-ils possibles ?\nLes parents doivent-ils être testés ?\nY a-t-il des recommandations pour les familles ?", "url": "https://questionsmedicales.fr/mesh/D030321?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndrome de Denys-Drash", "description": "Quel est le traitement principal pour l'insuffisance rénale ?\nDes traitements hormonaux sont-ils nécessaires ?\nComment gérer les tumeurs associées ?\nY a-t-il des soins de soutien disponibles ?\nLe suivi médical est-il important ?", "url": "https://questionsmedicales.fr/mesh/D030321?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndrome de Denys-Drash", "description": "Quelles sont les complications possibles ?\nLe syndrome augmente-t-il le risque de cancer ?\nDes complications psychologiques peuvent-elles survenir ?\nComment les complications sont-elles gérées ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D030321?mesh_terms=Prostatic+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndrome de Denys-Drash", "description": "Quels sont les facteurs de risque connus ?\nLe sexe influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes mutations génétiques sont-elles héréditaires ?\nY a-t-il des tests pour évaluer le risque ?", "url": "https://questionsmedicales.fr/mesh/D030321?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on le syndrome de Denys-Drash ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, l'analyse génétique et l'imagerie rénale." } }, { "@type": "Question", "name": "Quels tests génétiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests pour identifier des mutations dans le gène WT1 sont effectués." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent ce syndrome ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des malformations rénales, des anomalies génitales et des troubles de croissance." } }, { "@type": "Question", "name": "Les échographies sont-elles utiles ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les échographies rénales aident à détecter les anomalies structurelles." } }, { "@type": "Question", "name": "Le syndrome est-il héréditaire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est généralement hérité de manière autosomique dominante." } }, { "@type": "Question", "name": "Quels sont les symptômes principaux ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent l'insuffisance rénale, des anomalies génitales et des tumeurs." } }, { "@type": "Question", "name": "Y a-t-il des signes de dysfonctionnement hormonal ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des signes de dysfonctionnement hormonal peuvent apparaître, affectant la puberté." } }, { "@type": "Question", "name": "Les enfants sont-ils affectés dès la naissance ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent apparaître à la naissance ou se développer durant l'enfance." } }, { "@type": "Question", "name": "Le syndrome affecte-t-il la croissance ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des retards de croissance peuvent être observés chez les enfants atteints." } }, { "@type": "Question", "name": "Y a-t-il des symptômes psychologiques associés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes psychologiques peuvent survenir, liés à l'adaptation à la maladie." } }, { "@type": "Question", "name": "Peut-on prévenir le syndrome de Denys-Drash ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de prévention, mais un conseil génétique peut aider les familles à risque." } }, { "@type": "Question", "name": "Comment le conseil génétique aide-t-il ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il informe les familles sur les risques de transmission et les options disponibles." } }, { "@type": "Question", "name": "Les tests prénataux sont-ils possibles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests prénataux peuvent détecter des anomalies génétiques chez le fœtus." } }, { "@type": "Question", "name": "Les parents doivent-ils être testés ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage des parents peut identifier des porteurs de mutations génétiques." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour les familles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les familles doivent être informées des signes précoces et des soins médicaux nécessaires." } }, { "@type": "Question", "name": "Quel est le traitement principal pour l'insuffisance rénale ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "La dialyse ou la transplantation rénale est souvent nécessaire pour l'insuffisance rénale." } }, { "@type": "Question", "name": "Des traitements hormonaux sont-ils nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements hormonaux peuvent être requis pour corriger les anomalies sexuelles." } }, { "@type": "Question", "name": "Comment gérer les tumeurs associées ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les tumeurs peuvent nécessiter une chirurgie, une chimiothérapie ou une radiothérapie." } }, { "@type": "Question", "name": "Y a-t-il des soins de soutien disponibles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins de soutien psychologique et éducatif sont souvent recommandés." } }, { "@type": "Question", "name": "Le suivi médical est-il important ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est crucial pour surveiller l'évolution de la maladie." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance rénale terminale et les cancers associés." } }, { "@type": "Question", "name": "Le syndrome augmente-t-il le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients ont un risque accru de développer des tumeurs, notamment rénales." } }, { "@type": "Question", "name": "Des complications psychologiques peuvent-elles survenir ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications psychologiques comme l'anxiété et la dépression sont possibles." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent une approche multidisciplinaire incluant divers spécialistes." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux de syndrome et des mutations génétiques." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le syndrome est plus fréquent chez les garçons en raison des anomalies sexuelles." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'y a pas de preuves solides liant des facteurs environnementaux au syndrome." } }, { "@type": "Question", "name": "Les mutations génétiques sont-elles héréditaires ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations dans le gène WT1 sont souvent héritées de manière autosomique dominante." } }, { "@type": "Question", "name": "Y a-t-il des tests pour évaluer le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent évaluer le risque pour les membres de la famille." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o... PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u... More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ... Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...